Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) – Pipeline Review, H1 2017’, provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders under development targeting Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

ArQule Inc

Astellas Pharma Inc

AstraZeneca Plc

Blueprint Medicines Corp

Bristol-Myers Squibb Company

Eisai Co Ltd

Eli Lilly and Company

Genosco Inc

H3 Biomedicine Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

NGM Biopharmaceuticals Inc

Novartis AG

Principia Biopharma Inc

Tasly Pharmaceutical Group Co Ltd

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Companies Involved in Therapeutics Development

Amgen Inc

ArQule Inc

Astellas Pharma Inc

AstraZeneca Plc

Blueprint Medicines Corp

Bristol-Myers Squibb Company

Eisai Co Ltd

Eli Lilly and Company

Genosco Inc

H3 Biomedicine Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

NGM Biopharmaceuticals Inc

Novartis AG

Principia Biopharma Inc

Tasly Pharmaceutical Group Co Ltd

Vichem Chemie Research Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Drug Profiles

ARQ-087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-5878 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-709 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-9931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FGF-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golvatinib tartrate + lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-62079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infigratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-463588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2874455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSLB-1344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting

Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting

May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting

May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting

Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting

Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017

Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting

Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma

Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences

Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug

Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting

Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint

Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by ArQule Inc, H1 2017

Pipeline by Astellas Pharma Inc, H1 2017

Pipeline by AstraZeneca Plc, H1 2017

Pipeline by Blueprint Medicines Corp, H1 2017

Pipeline by Bristol-Myers Squibb Company, H1 2017

Pipeline by Eisai Co Ltd, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Genosco Inc, H1 2017

Pipeline by H3 Biomedicine Inc, H1 2017

Pipeline by Incyte Corp, H1 2017

Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by NGM Biopharmaceuticals Inc, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Principia Biopharma Inc, H1 2017

Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Pipeline by Vichem Chemie Research Ltd, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports